PlainPharmaWatch

CMS Open Payments · Tool

Renalytix AI, Inc. vs Ipsen Innovation

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Renalytix AI, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 2,909, versus 763 for the other company. Its single largest recorded recipient represents 38.1% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Renalytix AI, Inc.
HHI 2,909 · top recipient 38.1%
Ranked #580 of 1,838 companies by HHI
Ipsen Innovation
HHI 763 · top recipient 13.8%
Ranked #1,143 of 1,838 companies by HHI

Payment Overview

Company A

Renalytix AI, Inc.

Total Payments
$5.9M
% of Industry
0.0%
Transactions
1,603
Avg per Transaction
$3.7K
Recipients
1,559
Avg per Recipient
$3.8K
Payment Types
2
Top Payment Type
Consulting Fee
Company B

Ipsen Innovation

Total Payments
$5.8M
% of Industry
0.0%
Transactions
4,466
Avg per Transaction
$1.3K
Recipients
124
Avg per Recipient
$47.2K
Payment Types
4
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Renalytix AI, Inc. vs Ipsen Innovation - total reported payments in CMS Open Payments PY2024

Renalytix AI, Inc.$5.9MIpsen Innovation$5.8M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Renalytix AI, Inc.

Consulting Fee $100.0K

76.3%

Food and Beverage $31.1K

23.7%

Ipsen Innovation

Consulting Fee $226.8K

64.9%

Travel and Lodging $79.2K

22.7%

Compensation for Services Other Than Consulting $39.1K

11.2%

Food and Beverage $4.3K

1.2%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Renalytix AI, Inc.

  1. 1

    STEVEN COCA

    $50,000.00 · 10 txns

  2. 2

    GIRISH N NADKARNI

    $50,000.00 · 10 txns

  3. 3

    ARVIND MADAN

    $292.10 · 6 txns

  4. 4

    WILLIAM E TORRES

    $233.89 · 7 txns

  5. 5

    SARAH E LEMOINE

    $198.59 · 11 txns

Ipsen Innovation

  1. 1

    CHRISTOPHER L BOWLUS

    $48,265.65 · 9 txns

  2. 2

    JACK DAVID SCHIM

    $42,013.98 · 10 txns

  3. 3

    ATUL PATEL

    $41,626.86 · 9 txns

  4. 4

    The Childrens Hospital Of Philadelp

    $33,332.00 · 1 txns

  5. 5

    MONICA VERDUZCO-GUTIERREZ

    $25,905.44 · 7 txns

Summary Comparison

Metric Renalytix AI, Inc. Ipsen Innovation
Total Payments $5.9M $5.8M
% of Industry Total 0.0% 0.0%
Transaction Count 1,603 4,466
Avg per Transaction $3.7K $1.3K
Recipient Count 1,559 124
Avg per Recipient $3.8K $47.2K
Payment Type Count 2 4
Top Payment Type Consulting Fee Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.